+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 34 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating HLX22 combined with trastuzumab and chemotherapy as a first-line treatment for patients with HER2-positive locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction. This phase 3, randomized, double-blind study compares this combination against trastuzumab plus chemotherapy with or without pembrolizumab. The trial aims to assess the efficacy and safety of adding HLX22 in this patient population. Participants will be randomly assigned in a 11 ratio to either the experimental group receiving HLX22 15 mgkg plus trastuzumab and chemotherapy XELOX with or without a placebo for pembrolizumab every three weeks, or the control group receiving placebo for HLX22 plus trastuzumab and chemotherapy XELOX with or without pembrolizumab also every three weeks. Treatment continues until clinical benefit is lost, intolerable side effects occur, death, withdrawal, or other protocol-specified reasons. Throughout the study, participants will have their disease progression monitored by an independent radiology review committee using RECIST v1.1 criteria for up to five years, along with overall survival and response rates. Safety will be regularly assessed by tracking adverse events. The study includes multiple assessments to evaluate treatment effects, and participants will be followed for long-term outcomes during the trial period.

Age: 18Years +All GendersPhase 3
208 locations
C

Actively Recruiting

Researchers are comparing two treatment combinations for adults with advanced nonsquamous non-small cell lung cancer NSCLC that is stage IV or advanced stage IIIBC, specifically with a KRAS p.G12C mutation and no PD-L1 expression. The study evaluates progression-free survival and overall survival between participants receiving sotorasib with chemotherapy and those receiving pembrolizumab with chemotherapy. This is a phase 3, randomized, open-label study aiming to find which frontline therapy might better manage this type of lung cancer. Participants are randomly assigned to one of two groups one group receives sotorasib orally combined with carboplatin and pemetrexed chemotherapy, and the other group receives pembrolizumab given intravenously combined with the same chemotherapy agents. Treatments are given as front-line therapy for their cancer. The study measures the effects of these combinations over time, including tumor response and quality of life changes. During the study, participants will be closely monitored for progression-free survival, overall survival, and other outcomes related to tumor response and quality of life through questionnaires. Researchers will track treatment-emergent adverse events, vital signs, and lab tests to evaluate safety. The study includes follow-up assessments for up to approximately 5.5 years, allowing comprehensive evaluation of long-term outcomes and side effects. Participant involvement includes regular visits for treatment administration and assessments throughout the study period.

Age: 18Years - 100YearsAll GendersPhase 3
424 locations
G

Actively Recruiting

Researchers are evaluating the safety of telisotuzumab vedotin in adults with previously treated non-squamous non-small cell lung cancer NSCLC that overexpresses the c-Met protein. This phase 2, open-label study aims to assess treatment-emergent adverse events, changes in disease activity, and how the drug behaves in the body. Approximately 150 participants will be enrolled worldwide and randomly assigned to one of three telisotuzumab vedotin dose groups. Participants will receive intravenous infusions of telisotuzumab vedotin at different doses as a monotherapy, administered over a three-year study period. The study compares three dosing regimens given by IV infusion, with participants assigned to one of three groups in a 111 ratio. Each participant will be treated and followed for up to three years to monitor safety and response. During the study, participants will attend regular visits at hospitals or clinics for medical assessments, blood tests, and monitoring of side effects. Questionnaires will be completed to report symptoms and quality of life. Researchers will track adverse events, including lung disease, neuropathy, and eye disorders, as well as treatment response and survival outcomes. The study includes ongoing safety monitoring and evaluation of drug levels in the blood throughout the treatment period.

Age: 18Years +All GendersPhase 2
83 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the InnAVasc Arteriovenous Graft IG for hemodialysis access in patients with end-stage renal disease ESRD. The study focuses on how well the graft maintains secondary patency at 6 months and monitors any device-related adverse events during this period. The trial is designed for ESRD patients who need hemodialysis and for whom an arteriovenous graft is the next best access option. Participants will receive the InnAVasc AVG surgically implanted in the forearm or upper arm, using standard vascular surgical methods. The graft placement may be in a straight configuration in the upper arm or looped in the forearm or upper arm, avoiding placement across the elbow bend. Patients will continue or start antiplatelet therapy as advised by their physician. The study includes follow-up visits and assessments up to 2 years after implantation to monitor graft use and safety. Participants will be asked to provide informed consent and will undergo periodic evaluations including monitoring of graft patency, successful cannulation within 7 days post-surgery, and sustained use over 24 months. Safety assessments focus on adverse events related to the device. Throughout the trial, participants will attend scheduled visits to support ongoing data collection and safety monitoring over the 2-year period following graft implantation.

Age: 18Years - 90YearsAll GendersPhase Not Applicable
22 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease COPD who are already receiving inhaled maintenance therapy and have experienced recent COPD exacerbations. This Phase 3, multicenter, randomized, double-blind, placebo-controlled study aims to understand how tezepelumab impacts COPD outcomes compared to a placebo. Participants will receive monthly subcutaneous injections of one of two doses of tezepelumab or a matching placebo. The treatment period lasts a minimum of 52 weeks and up to 76 weeks. Following treatment, there is a 12-week safety follow-up without active treatment to monitor participants. Throughout the study, participants will be monitored regularly to assess lung function, COPD symptoms, and exacerbation rates. Researchers will collect data on lung function tests, symptom questionnaires, and exacerbation frequency up to 76 weeks. Blood samples will be taken to study drug levels and immune responses. The total participation time for each individual includes the treatment period plus the safety follow-up phase.

Age: 40Years - 80YearsAll GendersPhase 3
284 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and tolerability of a new multivalent pneumococcal vaccine called PG4 in healthy infants. The study compares this new vaccine to the currently used 20-valent pneumococcal conjugate vaccine 20vPnC to see how well they protect against infections like pneumonia, meningitis, and ear infections caused by Streptococcus pneumoniae. The trial is a Phase 3, randomized, double-blinded study involving about 2400 infants around 2 months old. Participants will be randomly assigned to receive either the new PG4 vaccine or the 20vPnC vaccine. Both vaccines are given as injections into the left thigh muscle at 2, 4, 6, and between 12 to 15 months of age. The study lasts about 16 to 19 months, during which infants will have six clinic visits and one phone call to monitor their health and any side effects. During these visits, parents or legal guardians will report any local reactions, systemic events, or other adverse effects experienced by the infant after each vaccine dose. Researchers will track events occurring within seven days after each dose, as well as serious adverse events up to six months following the last dose. The goal is to understand the safety profile of the new vaccine compared to the existing one over the course of the study period.

Age: 42Days - 98DaysAll GendersPhase 3
78 locations
P

Actively Recruiting

Healthy Volunteer

Researchers are studying the safety and immune response of a fifth dose of the Lyme disease vaccine called VLA15 in healthy individuals aged 7 years and older who have already received four doses of this vaccine. This Phase 3 trial compares the effects of the vaccine against a placebo saline to better understand its protection against Lyme disease. The study is randomized, placebo-controlled, and double-blinded, aiming to assess tolerability and immune response. Participants receive one injection, either VLA15 or saline, into the muscle of the upper arm at their first visit. They are randomized in a 51 ratio to either vaccine or placebo. The timing of the fifth dose varies, occurring either one or two years after the fourth dose from a previous study. The trial includes about 1712 participants and uses an independent data monitoring committee to oversee safety. During approximately 12 months of participation, individuals will attend four clinic visits. These visits include health checks, blood draws to measure immune response, and receiving the study injection during the first visit. Researchers will monitor local and systemic reactions within seven days post-injection, adverse events up to one month, and longer-term safety for up to a year. The main outcomes focus on immune responses to different parts of the vaccine and recording any side effects or new medical conditions.

Age: 7Years +All GendersPhase 3
22 locations
E

Actively Recruiting

This trial focuses on premenopausal women aged 18 to 55 with hormone receptor-positive breast cancer, either early-stage or advanced. Researchers are evaluating how well ZOLADEX 10.8 mg suppresses ovarian function by measuring luteinizing hormone LH levels. The study aims to assess the consistency and degree of ovarian suppression achieved with this treatment. Participants receive two doses of ZOLADEX 10.8 mg as subcutaneous injections, administered on Day 1 and Day 85. The trial includes two parallel groups based on breast cancer stage, with treatment effects monitored over several weeks. The study is open-label, meaning both participants and researchers know the treatment being given. Throughout the study, participants undergo regular assessments of LH, estradiol levels, and menstrual status at weeks 6, 12, 18, and 24. These evaluations help determine how effectively ovarian suppression is maintained. Safety and adherence are monitored, with the primary outcome focused on LH values below a specific threshold at week 6. The total participation lasts at least 24 weeks, with follow-up visits to track hormonal changes and menstrual status.

Age: 18Years - 55YearsFEMALEPhase 1
26 locations
C

Actively Recruiting

Researchers are investigating whether combining chemotherapy with the immunotherapy drug pembrolizumab improves overall survival compared to pembrolizumab alone in older adults aged 70 and above with advanced stage IIIB-IV non-small cell lung cancer. This phase III trial focuses on a vulnerable population and aims to evaluate survival, disease progression, treatment response, toxicity, quality of life, and other health factors. The study also explores how gut microbes and geriatric assessments relate to treatment outcomes. Participants are randomly assigned to one of two groups. In the first group, patients receive pembrolizumab intravenously every 21 days for four cycles, followed by maintenance doses every 21 or 42 days for up to two years if there is no disease progression or severe side effects. In the second group, patients receive pembrolizumab plus a chemotherapy regimen chosen by the investigator, given intravenously on specific schedules for four cycles, followed by the same pembrolizumab maintenance as the first group. Imaging tests like MRI, CT, and PET scans are done at the start and throughout treatment. During the study, participants undergo regular clinical assessments, imaging, and laboratory tests to monitor their cancer and overall health. Follow-up visits occur every three months for up to two years and then every six months until five years after starting treatment. Researchers measure overall survival, progression-free survival, response rates, side effects, and quality of life. The study also collects patient-reported information and evaluates safety and tolerability over time.

Age: 70Years +All GendersPhase 3
329 locations
O

Actively Recruiting

Researchers are evaluating the Freenome Multiomics Blood Test as a new way to screen for lung cancer in people at high risk. This observational study includes adults aged 50 and older who are current or former smokers with a significant smoking history. The goal is to see how well this blood test works alongside the standard Low-Dose Computed Tomography LDCT screening to detect lung cancer early. Participants will provide a blood sample of 50 ml that will be tested and stored by Freenome or its designee. They will also undergo a standard LDCT chest scan, ideally on the same day as the blood draw or within 45 days afterward. The study collects additional information such as medical history, lifestyle, environmental exposures, and results from diagnostic tests related to lung cancer detection. Participants will be monitored for at least 24 months following their baseline chest CT scan to track health outcomes. Researchers will review clinical data, imaging reports, and lab results during this period. The main outcome measured is the blood tests sensitivity and specificity in detecting lung cancer at 12 months, with additional measurements at 24 months. The study may end early if participants withdraw or pass away.

Age: 50Years +All Genders
36 locations

1-10 of 34

1